Select a Language:
The ECEAE has today welcomed the formation of a new working group at the European Medicines Agency (EMA) to look at ways to replace, reduce and refine animal testing on medicines.
The EMA’s new working group met for the first time this week. It plans to initiate projects and provide advice to the Agency on how pharmaceutical companies can use fewer animals in their testing programmes.
The ECEAE’s Senior Science Advisor, Dr Katy Taylor says: “We welcome the move by the European Medicines Agency to look into the very serious issue of animal testing for pharmaceuticals.”
She continues, “The ECEAE has been asking the Agency for several years to set up such a group and so we are delighted that our call has finally been answered. Recently we have been particularly concerned by animal testing continuing to take place despite no longer being required by the EMA, and so it is vital that this issue is addressed by the Agency. We look forward to hearing from the EMA about its plans and ultimately to see a reduction in the number of animals used to test medicines”.
The European Medicines Agency is the EU body responsible for the authorisation of human and veterinary medicines across the EU. The ECEAE is a registered animal protection stakeholder at the agency as part of the International umbrella organisation, the International Council on Animal Protection in Pharmaceutical Programmes (ICAPPP).